Jeisys Medical Inc
KOSDAQ:287410
Jeisys Medical Inc
Other Current Liabilities
Jeisys Medical Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jeisys Medical Inc
KOSDAQ:287410
|
Other Current Liabilities
₩14.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
971%
|
CAGR 10-Years
N/A
|
|
|
I
|
I Sens Inc
KOSDAQ:099190
|
Other Current Liabilities
₩30B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Other Current Liabilities
₩30.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
W
|
Won Tech Co Ltd
KOSDAQ:336570
|
Other Current Liabilities
₩19.5B
|
CAGR 3-Years
1 767%
|
CAGR 5-Years
528%
|
CAGR 10-Years
N/A
|
|
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
Other Current Liabilities
₩6.7B
|
CAGR 3-Years
68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Seers Technology Co Ltd
KOSDAQ:458870
|
Other Current Liabilities
₩1.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jeisys Medical Inc
Glance View
Jeisys Medical, Inc. manufactures and develops products used by plastic surgeons, dermatologist, physicians and health professionals. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-05-08. The firm manufactures and sells skin care medical devices such as ULTRAcel Q+, POTENZA, and other products. In addition, the Company also provides consumables such as cartridges and tips.
See Also
What is Jeisys Medical Inc's Other Current Liabilities?
Other Current Liabilities
14.1B
KRW
Based on the financial report for Jun 30, 2024, Jeisys Medical Inc's Other Current Liabilities amounts to 14.1B KRW.
What is Jeisys Medical Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
971%
Over the last year, the Other Current Liabilities growth was -27%. The average annual Other Current Liabilities growth rates for Jeisys Medical Inc have been 32% over the past three years , 971% over the past five years .
